Financial Data and Key Metrics Changes - The company reported net product sales of $75.9 million for the first quarter, representing a 90% increase year-over-year and continued sequential growth [26][30] - Net sales for VILSPARI grew 182% year-over-year and 13% compared to the previous quarter, reflecting strong demand and uptake [7][26] - The net loss for the first quarter was $41.2 million, or $0.47 per basic share, compared to a net loss of $136.1 million, or $1.76 per basic share for the same period in 2024 [30] Business Line Data and Key Metrics Changes - VILSPARI generated approximately $56 million in net product sales in the first quarter, driven by an increasing prescriber base and deepening penetration among experienced prescribers [19][20] - Thiola and Thiola EC contributed $20 million in net product sales for the first quarter [26] - The company anticipates continued strong demand for VILSPARI in IgA nephropathy, with projected net product sales growth throughout the year [31] Market Data and Key Metrics Changes - The European Commission and MHRA in the UK converted FILSPARI's conditional approvals to full approvals for the treatment of adults with IgA nephropathy, enabling broader access across Europe and the UK [8] - Approximately 75% of nephrologists are now targeting proteinuria below 0.5 grams per gram, with nearly a third targeting even more ambitious goals of 0.3 grams [23] Company Strategy and Development Direction - The company aims to solidify VILSPARI's foundational positioning in IgA nephropathy and unlock additional growth through a potential new indication in FSGS [6] - The company is preparing for a potential launch of VILSPARI for FSGS, which is expected to be a significant opportunity, potentially larger than in IgA nephropathy [10][24] - The company is committed to advancing its investigational therapy PEG T for classical homocystinuria (HCU) and plans to restart patient enrollment in the Phase III HARMONY study next year [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategy with strong fundamentals and a clear focus on executing key priorities [11] - The company is monitoring legislative developments and geopolitical uncertainties but believes that any potential tariffs on pharmaceutical products would not have a material impact on VILSPARI [31] - Management highlighted the importance of the upcoming finalization and publication of the KDIGO guidelines, which are expected to reinforce the shift to earlier and more ambitious treatments [23][100] Other Important Information - The company expects to receive a $17.5 million milestone payment from CSL V4 due to the recent conversion of FILSPARI's conditional approval to full approval in Europe [30] - The company has maintained broad coverage across payers, with criteria easing following the label expansion at full approval [21] Q&A Session Summary Question: Can you elaborate on any interactions with the agency regarding the sNDA for FSGS? - Management reported that interactions with the FDA have been progressing as expected, with consistency in the review process compared to previous experiences with the IGAN indication [34][35] Question: What do you think the label for FSGS will look like? - The expectation is that the indication statement will be for the treatment of FSGS in patients ages eight and up, based on the broad inclusion criteria of the duplex study [39][42] Question: How is the recent approval of Novartis' therapy impacting your sales reps in the field? - Management noted that it is early to assess the impact, but continued demand growth has been observed, indicating confidence in FILSPARI's profile [48][51] Question: Can you provide more detail on gross to net comments? - Management indicated that gross to net discounts are expected to be in the low twenties, with a more even distribution throughout the year compared to the previous year [56][58] Question: What is the split between new versus repeat prescribers for FILSPARI? - The split is slightly skewed towards experienced prescribers, with a healthy continuation of new prescribers as well [82]

Financial Performance - Total revenue for Q1 2025 was $81.732 million, a 97% increase from $41.374 million in Q1 2024[19]. - Net product sales reached $75.861 million, up 90% from $39.984 million in the same period last year[19]. - Operating loss for Q1 2025 was $42.674 million, compared to a loss of $139.237 million in Q1 2024, indicating a significant improvement[19]. - The company reported a net loss of $41.226 million for Q1 2025, a decrease from a net loss of $136.061 million in Q1 2024[19]. - For the three months ended March 31, 2025, the net loss from continuing operations was $41,226 thousand, a decrease from a net loss of $135,958 thousand in the same period of 2024, representing a 70.7% improvement[25]. - For the three months ended March 31, 2025, the company reported a net loss of $41.2 million, or $(0.47) per share, compared to a net loss of $136.1 million, or $(1.76) per share for the same period in 2024[131]. - Revenue for the three months ended March 31, 2025, was $81.7 million, a significant increase from $41.4 million in the same period of 2024[149]. Cash and Assets - Cash and cash equivalents increased to $61.897 million as of March 31, 2025, up from $58.535 million at the end of 2024[16]. - Total assets decreased to $548.799 million as of March 31, 2025, down from $594.125 million at the end of 2024[16]. - Total liabilities were $515.976 million as of March 31, 2025, compared to $535.048 million at the end of 2024, reflecting a reduction in liabilities[16]. - As of March 31, 2025, the company had cash equivalents and marketable debt securities totaling approximately $322.2 million[233]. - The company’s inventory decreased from $41.9 million as of December 31, 2024, to $38.0 million as of March 31, 2025[141]. - Accounts receivable increased to $34.4 million as of March 31, 2025, up from $27.1 million as of December 31, 2024[142]. Expenses - Research and development expenses for Q1 2025 were $46.889 million, slightly down from $49.420 million in Q1 2024[19]. - Selling, general and administrative expenses increased to $72.838 million in Q1 2025, compared to $64.223 million in Q1 2024[19]. - The company recognized a total of $13.8 million in restructuring costs as of December 31, 2024, primarily related to one-time termination benefits[65]. - Total share-based compensation for continuing operations was $11.5 million for the three months ended March 31, 2025, compared to $9.8 million for the same period in 2024[140]. Product Development and Regulatory Approvals - FILSPARI® received full FDA approval on September 5, 2024, for slowing kidney function decline in adults with primary IgAN, following positive long-term results from the PROTECT Study[29][30]. - The company completed a Type C meeting with the FDA in February 2025 and submitted an sNDA for FILSPARI for the treatment of FSGS, supported by results from the Phase 3 DUPLEX Study[34]. - Renalys Pharma initiated an open label registration study of sparsentan in Japan in the second quarter of 2024, with full enrollment achieved by January 2025[32]. - Pegtibatinase is currently in a voluntary enrollment pause in the Phase 3 HARMONY Study to address manufacturing scale-up issues, with ongoing support for currently enrolled patients[37]. - The company focuses on expanding its product pipeline through licenses and acquisitions to address serious unmet medical needs in rare diseases[28]. Sales and Revenue Recognition - The company sells its products primarily in the United States, which represents over 98% of net product sales[70]. - Revenue from product sales is recognized upon delivery, with payment terms generally within 30 days from shipment[71]. - FILSPARI sales reached $55.881 million in Q1 2025, compared to $19.834 million in Q1 2024, reflecting a significant growth[78]. - The company recognized $5.9 million in license and collaboration revenue for Q1 2025, up from $1.4 million in Q1 2024[80]. Debt and Financing - The Company completed a repurchase of $207.1 million of 2025 Notes for a total of $213.8 million, resulting in a $7.6 million loss on extinguishment of debt[123]. - The 2025 Notes bear an annual interest rate of 2.50% and will mature on September 15, 2025[117]. - The total remaining principal amount outstanding under the 2025 Notes was $68.9 million as of March 31, 2025[123]. - The Company received net proceeds of $306.4 million from the issuance of the 2029 Notes after deducting $9.9 million in commissions and offering expenses[114]. - The effective interest rate on the 2029 Notes is 2.74%[116]. - The initial conversion rate for the 2029 Notes is 31.3740 shares per $1,000 principal amount, equating to an initial conversion price of approximately $31.87 per share[115]. - The Company incurred approximately $9.9 million in debt issuance costs related to the 2029 Notes, which are being amortized over the expected life of the notes[116]. - The total interest expense recognized for the three months ended March 31, 2025, was $2.9 million, compared to $2.8 million for the same period in 2024[126]. Marketable Securities and Investments - As of March 31, 2025, the company's marketable debt securities totaled $260.345 million, down from $312.166 million as of December 31, 2024[90]. - Unrealized losses on available-for-sale marketable debt securities as of March 31, 2025, totaled $19, with a fair value of $81.960 million[92]. Contingent Liabilities and Agreements - The company has contingent cash payments of up to $427.0 million related to the acquisition of Orphan Technologies Limited, based on certain development and commercialization milestones[133]. - The Renalys License Agreement allows the company to receive up to $120 million in milestone payments and tiered royalties on net sales in specified Asian countries[82].

Financial Data and Key Metrics Changes - The company reported net product sales of $75.9 million for Q1 2025, representing a 90% increase year-over-year and continued sequential growth [27] - Net sales for VILSPARI grew 182% year-over-year and 13% compared to the previous quarter, reflecting strong demand and uptake [6][20] - The net loss for Q1 2025 was $41.2 million, or $0.47 per basic share, compared to a net loss of $136.1 million, or $1.76 per basic share, for the same period in 2024 [32] Business Line Data and Key Metrics Changes - VILSPARI maintained strong momentum with $55.9 million in net product sales for Q1 2025, despite higher gross-to-net discounts due to insurance coverage changes [27][28] - Thiola and Thiola EC contributed $20 million in net product sales for the first quarter [28] - The company expects to receive a $17.5 million milestone payment from CSL V4 due to the conversion of VILSPARI's conditional approval to full approval in Europe [32] Market Data and Key Metrics Changes - The European Commission and MHRA in the UK converted FILSPARI's conditional approvals to full approvals for the treatment of adults with IgA nephropathy, enabling broader access across Europe and the UK [7] - Approximately 75% of nephrologists are now targeting proteinuria below 0.5 grams per gram, with nearly a third targeting even more ambitious goals of 0.3 grams [25] Company Strategy and Development Direction - The company aims to solidify VILSPARI's foundational positioning in IgA nephropathy and unlock additional growth through a potential new indication in FSGS [5] - The company is preparing for a potential launch of VILSPARI for FSGS, which is expected to be a significant opportunity, potentially larger than in IgA nephropathy [10][26] - The company is committed to advancing its investigational therapy PEG T for classical homocystinuria (HCU) and plans to restart patient enrollment in the Phase III HARMONY study next year [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategy with strong fundamentals and a clear focus on executing key priorities [11] - The company anticipates continued strong demand for FILSPARI and IgA nephropathy, projecting meaningful growth in net product sales throughout the year [33] - Management is monitoring legislative developments and geopolitical uncertainties but believes that potential tariffs on pharmaceutical products would not have a material impact on VILSPARI [33] Other Important Information - The company reported a decrease in R&D expenses to $46.9 million for Q1 2025, down from $49.4 million in the same period in 2024 [29] - Selling, general, and administrative expenses increased to $72.8 million for Q1 2025, compared to $64.2 million for the same period in 2024, largely due to increased investment in the FILSPARI launch [30] Q&A Session Summary Question: Can you elaborate on any interactions with the agency regarding the sNDA for FSGS? - Management indicated that interactions with the FDA have been consistent and progressing as expected, similar to previous experiences with the IGAN indication [36][38] Question: What do you think the label for FSGS will look like? - The expectation is that the indication will be for the treatment of FSGS in patients ages eight and up, based on the broad inclusion criteria of the duplex study [42][45] Question: How is the recent approval of Novartis' therapy impacting your sales reps in the field? - Management noted that it is early to assess the impact, but continued demand for FILSPARI has been observed, indicating confidence in its efficacy profile [50][52] Question: What is the impact of the removal of the REMS program on new patient starts in IGAN? - Management stated that REMS has not been an obstacle to performance and anticipates that modifications will enhance convenience for patients and physicians [76][78] Question: What is the split between new versus repeat prescribers for FILSPARI? - The split is slightly skewed towards experienced prescribers, with a healthy continuation of new prescribers as well [86]

Core Points - The European Commission has converted the conditional marketing approval of FILSPARI (sparsentan) into a standard marketing authorization for the treatment of IgA nephropathy (IgAN) [1][2] - This decision follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) in February 2025 [1][2] - The approval is based on comprehensive data from the phase-III PROTECT study, which demonstrated that FILSPARI significantly slowed kidney function decline compared to irbesartan [1][2][9] Company Overview - CSL Vifor is a global partner specializing in pharmaceuticals and innovative therapies for iron deficiency and nephrology, headquartered in St. Gallen, Switzerland [3] - Travere Therapeutics is a biopharmaceutical company focused on developing therapies for rare diseases, emphasizing the urgent need for treatment options [5] Product Information - FILSPARI is the only Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved in Europe for IgAN, currently available in Germany, Austria, and Switzerland [3][11] - It is a non-immunosuppressive therapy with high selectivity for the endothelin A receptor and the angiotensin II subtype 1 receptor [10][11] Clinical Study Insights - The PROTECT study is one of the largest interventional studies in IgAN, involving 404 patients and comparing the efficacy of FILSPARI to irbesartan [8][9] - The study met its primary endpoint, showing a mean reduction in proteinuria of 49.8% for FILSPARI compared to 15.1% for irbesartan after 36 weeks [9]

Core Viewpoint - Vertex Pharmaceuticals (VRTX) is expected to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended March 2025, with the consensus outlook being crucial for assessing the company's earnings picture [1] Earnings Expectations - The upcoming earnings report is anticipated to be released on May 5, 2025, with a consensus EPS estimate of $4.22, reflecting an 11.3% decrease year-over-year, while revenues are projected to be $2.82 billion, up 4.8% from the previous year [3][2] - A positive surprise in earnings could lead to a stock price increase, while a miss could result in a decline [2] Estimate Revisions - The consensus EPS estimate has been revised 0.15% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4] - The Zacks Earnings ESP (Expected Surprise Prediction) model suggests that a positive or negative reading can indicate the likely deviation of actual earnings from the consensus estimate, with a positive reading being a strong predictor of an earnings beat [6][7] Earnings Surprise History - Vertex has beaten consensus EPS estimates in two out of the last four quarters, with a recent surprise of -0.25% when it reported earnings of $3.98 against an expectation of $3.99 [12][13] Industry Comparison - Another company in the same industry, Travere Therapeutics (TVTX), is expected to report a loss of $0.55 per share, which represents a year-over-year increase of 68.8%, with revenues projected at $74.33 million, up 79.7% from the previous year [17] - Travere has an Earnings ESP of 11.18% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate, despite not having beaten estimates in the last four quarters [18]